XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment and Geographical Information | 9 Months Ended
--- | ---
Sep. 30, 2018
Segment Reporting [Abstract] |
Segment and Geographical Information | Segment and Geographical Information The CODM is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company’s segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The two operating segments, which are the same as the Company’s two reportable segments, are as follows:
• | Automation and Analytics. The Automation and Analytics segment is organized around the design, manufacturing, selling, and servicing of medication and supply dispensing systems; pharmacy inventory management systems; and related software. The Automation and Analytics products are designed to enable the Company’s customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care, and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, the Company’s systems can be tailored to specific customer needs. The financial results of InPharmics acquired in the second quarter of 2017 are included in the Automation and Analytics segment.
• | Medication Adherence. The Medication Adherence segment includes solutions to assist patients to remain adherent to their medication regimens. These solutions are comprised of a variety of tools and aids that may be directly used by a pharmacist or a healthcare provider in their direct care for a patient, or the patient themselves, and include software-based systems and medication adherence packaging. Software solutions primarily operate on the Omnicell Patient Engagement platform, a subscription-based software system which provides an environment for patient engagement by clinicians. Services running on this platform include medication synchronization, immunization management, medication therapy management, and a number of tools used by clinicians to manage patient engagement workflows. Medication Adherence packaging is designed either for patient use in care environments where there is a caregiver present or for environments where the patient cares for him or herself and includes the manufacturing and selling of consumable medication blister cards, packaging equipment, and ancillary products and services.
The following tables summarize the financial performance of the Company’s reportable segments, including a reconciliation of income from segment operations to income from total operations:
| Three months ended September 30,
| 2018 |  | 2017
| Automation and Analytics |  | Medication Adherence |  | Total |  | Automation and Analytics |  | Medication Adherence |  | Total
| (In thousands)
Revenues: |  |  |  |  |  |  |  |  |  |  |
Product revenues | $ | 120,248 |  |  | $ | 29,461 |  |  | $ | 149,709 |  |  | $ | 110,368 |  |  | $ | 26,470 |  |  | $ | 136,838 |
Services and other revenues | 48,055 |  |  | 6,503 |  |  | 54,558 |  |  | 44,249 |  |  | 5,661 |  |  | 49,910 |
Total revenues | 168,303 |  |  | 35,964 |  |  | 204,267 |  |  | 154,617 |  |  | 32,131 |  |  | 186,748 |
Cost of revenues: |  |  |  |  |  |  |  |  |  |  |
Cost of product revenues | 54,958 |  |  | 24,191 |  |  | 79,149 |  |  | 59,811 |  |  | 19,914 |  |  | 79,725 |
Cost of services and other revenues | 22,214 |  |  | 3,995 |  |  | 26,209 |  |  | 19,929 |  |  | 2,275 |  |  | 22,204 |
Total cost of revenues | 77,172 |  |  | 28,186 |  |  | 105,358 |  |  | 79,740 |  |  | 22,189 |  |  | 101,929 |
Gross profit | 91,131 |  |  | 7,778 |  |  | 98,909 |  |  | 74,877 |  |  | 9,942 |  |  | 84,819 |
Operating expenses | 46,015 |  |  | 10,624 |  |  | 56,639 |  |  | 44,332 |  |  | 9,901 |  |  | 54,233 |
Income from operations | $ | 45,116 |  |  | $ | (2,846 | ) |  | $ | 42,270 |  |  | $ | 30,545 |  |  | $ | 41 |  |  | $ | 30,586 |
Corporate costs |  |  |  |  | 24,775 |  |  |  |  |  |  | 18,389 |
Income from operations |  |  |  |  | $ | 17,495 |  |  |  |  |  |  | $ | 12,197 |
| Nine months ended September 30,
| 2018 |  | 2017
| Automation and Analytics |  | Medication Adherence |  | Total |  | Automation and Analytics |  | Medication Adherence |  | Total
| (In thousands)
Revenues: |  |  |  |  |  |  |  |  |  |  |
Product revenues | $ | 335,441 |  |  | $ | 79,563 |  |  | $ | 415,004 |  |  | $ | 292,463 |  |  | $ | 73,371 |  |  | $ | 365,834 |
Services and other revenues | 142,633 |  |  | 17,922 |  |  | 160,555 |  |  | 132,908 |  |  | 17,601 |  |  | 150,509 |
Total revenues | 478,074 |  |  | 97,485 |  |  | 575,559 |  |  | 425,371 |  |  | 90,972 |  |  | 516,343 |
Cost of revenues: |  |  |  |  |  |  |  |  |  |  |
Cost of product revenues | 168,506 |  |  | 61,136 |  |  | 229,642 |  |  | 170,974 |  |  | 54,077 |  |  | 225,051 |
Cost of services and other revenues | 65,594 |  |  | 10,176 |  |  | 75,770 |  |  | 58,243 |  |  | 7,907 |  |  | 66,150 |
Total cost of revenues | 234,100 |  |  | 71,312 |  |  | 305,412 |  |  | 229,217 |  |  | 61,984 |  |  | 291,201 |
Gross profit | 243,974 |  |  | 26,173 |  |  | 270,147 |  |  | 196,154 |  |  | 28,988 |  |  | 225,142 |
Operating expenses | 142,572 |  |  | 31,119 |  |  | 173,691 |  |  | 139,902 |  |  | 31,196 |  |  | 171,098 |
Income (loss) from segment operations | $ | 101,402 |  |  | $ | (4,946 | ) |  | $ | 96,456 |  |  | $ | 56,252 |  |  | $ | (2,208 | ) |  | $ | 54,044 |
Corporate costs |  |  |  |  | 70,994 |  |  |  |  |  |  | 59,100 |
Income (loss) from operations |  |  |  |  | $ | 25,462 |  |  |  |  |  |  | $ | (5,056 | )
Significant Customers There were no customers that accounted for more than 10% of the Company’s total revenues for the three and nine months ended September 30, 2018 and 2017. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable as of September 30, 2018 and December 31, 2017. Geographical Information Revenues
| Three months ended September 30,
| 2018 |  | 2017
| (In thousands)
United States | $ | 180,635 |  |  | $ | 164,156 |
Rest of world (1) | 23,632 |  |  | 22,592 |
Total revenues | $ | 204,267 |  |  | $ | 186,748 |
| Nine months ended September 30,
| 2018 |  | 2017
| (In thousands)
United States | $ | 502,481 |  |  | $ | 447,877 |
Rest of world (1) | 73,078 |  |  | 68,466 |
Total revenues | $ | 575,559 |  |  | $ | 516,343 |
_________________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and Equipment, Net
| September 30, 2018 |  | December 31, 2017
| (In thousands)
United States | $ | 43,511 |  |  | $ | 34,899 |
Rest of world (1) | 6,973 |  |  | 7,696 |
Total property and equipment, net | $ | 50,484 |  |  | $ | 42,595 |
_________________________________________________
(1) | No individual country represented more than 10% of the respective totals.
Property and equipment, net is attributed to the geographic location in which it is located.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration